Coverage in the US: a map of the usual obstacles posts 31–51

Reading back through the coverage threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.

Everything in post #28 holds. The case it does not cover is the one I have.

Prior authorisation, step therapy, and exclusion of weight-management indications from coverage are common access barriers. The denial letter tells you which barrier you are facing.

The reason coverage keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.

Taking coverage seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.

Pharmacy practice varies between pharmacies within the same city, so two honest accounts can be entirely different.

If that reads as pedantic, it is, and it has saved me twice.

On coverage: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.

Building on post #34 rather than restating it.

United States: FDA licenses compounds. Prescribing and pharmacy practice are state-regulated. Compounds are prescription-only. Coverage is decided by individual plans, not nationally.

Marking my uncertainty on coverage explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.

Agreed on coverage, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.

The public assessment documents published at approval are free, detailed and largely unread here.

That has held every time I have looked, which is not the same as always.

Right — I had this wrong and I am glad to have read it before it mattered.

Offering a way to settle coverage rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.

The denial letter is the specification for the appeal. It states a criterion and the job is to demonstrate that criterion in the letter's own language.

I would put this at better than even and not much better.